For research use only. Not for therapeutic Use.
SKLB610 (CAT: I000477) is a potent multi-targeted inhibitor that demonstrates inhibitory activity against several angiogenesis-related tyrosine kinases, including VEGFR2 (vascular endothelial growth factor receptor 2), FGFR2 (fibroblast growth factor receptor 2), and PDGFR (platelet-derived growth factor receptor). By targeting these kinases, SKLB610 has the potential to disrupt signaling pathways involved in angiogenesis, which is the formation of new blood vessels. Angiogenesis plays a crucial role in tumor growth and metastasis.
| Catalog Number | I000477 |
| CAS Number | 1125780-41-7 |
| Synonyms | N-methyl-4-(4-(3-(trifluoromethyl)benzamido)phenoxy)picolinamide |
| Molecular Formula | C₂₁H₁₆F₃N₃O₃ |
| Purity | ≥95% |
| Target | VEGFR |
| Solubility | 10 mM in DMSO |
| Storage | Store at 4°C |
| InChI | InChI=1S/C21H16F3N3O3/c1-25-20(29)18-12-17(9-10-26-18)30-16-7-5-15(6-8-16)27-19(28)13-3-2-4-14(11-13)21(22,23)24/h2-12H,1H3,(H,25,29)(H,27,28) |
| InChIKey | WACDHHMEVMSODJ-UHFFFAOYSA-N |
| SMILES | O=C(NC1=CC=C(OC2=CC=NC(C(NC)=O)=C2)C=C1)C3=CC=CC(C(F)(F)F)=C3 |
| Reference | </br>1:The preparation and evaluation of water-soluble SKLB610 nanosuspensions with improved bioavailability. Huang Y, Luo X, You X, Xia Y, Song X, Yu L.AAPS PharmSciTech. 2013 Sep;14(3):1236-43. doi: 10.1208/s12249-013-0005-7. Epub 2013 Aug 10. PMID: 23934433 Free PMC Article</br>2:SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. Cao ZX, Zheng RL, Lin HJ, Luo SD, Zhou Y, Xu YZ, Zeng XX, Wang Z, Zhou LN, Mao YQ, Yang L, Wei YQ, Yu LT, Yang SY, Zhao YL.Cell Physiol Biochem. 2011;27(5):565-74. doi: 10.1159/000329978. Epub 2011 Jun 15. PMID: 21691074 Free Article |
